Cardiovascular Market Research Reports & Industry Analysis

Caused by heart and/or blood-vascular system disorders, cardiovascular (CDV) diseases kill almost 17 million people annually. The cardiovascular market can be divided the following key segments: cardiac surgery, cardiac rhythm management (abbreviated as CRM) and interventional cardiology. There is a wide range of products on offer in the market: defibrillators, introducers, catheters, pacemakers, among others.

The growth of the cardiovascular market is driven by the aging population, rising incidence of chronic CDV, innovations and technology advancements in the cardiovascular industry and constantly improving treatment capabilities. The USA is the largest cardiovascular market, with AstraZeneca , Merck & Co. , Bristol-Myers Squibb (BMS), Novartis , Sanofi-Aventis and Pfizerbeing amid the most prominent market participants.

Comprehensive assessment of the cardiovascular market at various geographical scales and over different time spans is provided in the research reports found under this catalogue. Data demand and supply trends, research and development activities, and leading market players are at hand in the reports. Moreover, future prospects for the market are disclosed in the research reports.

Found 388 publications
Restenosis Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... 2014 SUMMARY GlobalData's clinical trial report, “Restenosis Global Clinical Trials Review, H2, 2014' provides data on the Restenosis clinical trial scenario. This ... type and many more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / ...

Sep, 2014 88 pages
Hot Flashes Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... and data relating to the clinical trials on Hot Flashes. It includes an overview of the trial numbers and their recruitment status as per the ... more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Sep, 2014 109 pages
Hematoma Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... SUMMARY GlobalData's clinical trial report, “Hematoma Global Clinical Trials Review, H2, 2014' provides data on the Hematoma clinical trial scenario. This ... more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals ...

Sep, 2014 62 pages
Heart Valve Disease Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... Trials Review, H2, 2014' provides data on the Heart Valve Disease clinical trial scenario. This report provides elemental information and data relating ... Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies ...

Sep, 2014 71 pages
Heart Attack Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... and data relating to the clinical trials on Heart Attack. It includes an overview of the trial numbers and their recruitment status as per the ... more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Sep, 2014 78 pages
Giant Cell Arteritis Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... Trials Review, H2, 2014' provides data on the Giant Cell Arteritis clinical trial scenario. This report provides elemental information and data relating ... Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies ...

Sep, 2014 70 pages
Endothelial Dysfunction Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... and data relating to the clinical trials on Endothelial Dysfunction. It includes an overview of the trial numbers and their recruitment status as per the ... many more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals ...

Sep, 2014 76 pages
Eisenmenger Syndrome Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... and data relating to the clinical trials on Eisenmenger Syndrome. It includes an overview of the trial numbers and their recruitment status as per the ... Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies ...

Aug, 2014 81 pages
Edema Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... 2014 SUMMARY GlobalData's clinical trial report, “Edema Global Clinical Trials Review, H2, 2014' provides data on the Edema clinical trial scenario. This ... more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals ...

Aug, 2014 78 pages
Diastolic Hypertension Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... and data relating to the clinical trials on Diastolic Hypertension. It includes an overview of the trial numbers and their recruitment status as per the ... many more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals ...

Aug, 2014 70 pages
Diabetic Hypertension Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... and data relating to the clinical trials on Diabetic Hypertension. It includes an overview of the trial numbers and their recruitment status as per the ... Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies ...

Aug, 2014 62 pages
Zontivity (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 US$ 3,495.00

... has released its new PharmaPoint Drug Evaluation report, “Zontivity (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023”. The current ... initiates a strong platelet-activating, pro-thrombotic, signal transduction pathway. Zontivity locks the PAR1 receptor into a conformation that prevents thrombin ...

Jul, 2014 88 pages
Xarelto (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 US$ 3,495.00

... GlobalData has released its new PharmaPoint Drug Evaluation report, “Xarelto (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023”. The current ACS ... and fundamentally alter the ACS market, both medically and financially. Xarelto was approved in the EU for the prevention of non-valvular atrial ...

Jul, 2014 91 pages
PharmaPoint: Acute Coronary Syndrome - US Drug Forecast and Market Analysis to 2023 US$ 4,995.00

PharmaPoint: Acute Coronary Syndrome - US Drug Forecast and Market Analysis to 2023 SUMMARY GlobalData estimates that the total market size for the 7MM ... ACS market, both medically and financially. Of the 7MM forecast for acute coronary syndrome, the US market dominates the other six countries in sales for ...

Jul, 2014 233 pages
PharmaPoint: Acute Coronary Syndrome - Japan Drug Forecast and Market Analysis to 2023 US$ 4,995.00

PharmaPoint: Acute Coronary Syndrome - Japan Drug Forecast and Market Analysis to 2023 SUMMARY GlobalData estimates that the total market size for ... impact of key events as well the drivers and restraints affecting the Japan ACS market. REASONS TO BUY Understand and capitalize by identifying products ...

Jul, 2014 218 pages
PharmaPoint: Acute Coronary Syndrome - 5EU Drug Forecast and Market Analysis to 2023 US$ 6,995.00

PharmaPoint: Acute Coronary Syndrome - 5EU Drug Forecast and Market Analysis to 2023 SUMMARY GlobalData estimates that the total market size for the 7MM in 2013 was $12.3bn, comprised of $5.0bn in branded drug sales (40%) and $7.3bn in generic sales (60%). GlobalData expects that the ACS drug ...

Jul, 2014 277 pages
Evolocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 US$ 3,495.00

... GlobalData has released its new PharmaPoint Drug Evaluation report, “Evolocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023”. The current ... increases the body’s ability to filter LDL-C from the circulation. Evolocumab is one of several PCSK9 inhibitors navigating critical Phase III clinical ...

Jul, 2014 90 pages
Evacetrapib (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 US$ 3,495.00

... GlobalData has released its new PharmaPoint Drug Evaluation report, “Evacetrapib (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023”. The current ACS ... the cholesterol market with its own Phase III CETP inhibitor, evacetrapib. Like the researchers at Merck, the CETP inhibitor team at Eli Lilly ...

Jul, 2014 86 pages
Effient (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 US$ 3,495.00

... has released its new PharmaPoint Drug Evaluation report, “Effient (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023”. The current ... of P2Y12 blocks key signaling events in platelets that lead to coagulation. Effient is supplied as 10mg tablets and is administered as a 60mg loading dose during ...

Jul, 2014 60 pages
Crestor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 US$ 3,495.00

... GlobalData has released its new PharmaPoint Drug Evaluation report, “Crestor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023”. The current ... . It is the most potent of all of the HMG-CoA reductase inhibitors. Crestor faces steep competition from the generic statins, especially atorvastatin, ...

Jul, 2014 60 pages
Cangrelor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 US$ 3,495.00

... GlobalData has released its new PharmaPoint Drug Evaluation report, “Cangrelor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023”. The current ... 2012 agreement, The Medicines Company will not have marketing rights to cangrelor in Japan. GlobalData assumes, for this forecast, that AstraZeneca will ...

Jul, 2014 88 pages
Brilinta (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 US$ 3,495.00

... GlobalData has released its new PharmaPoint Drug Evaluation report, “Brilinta (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023”. The current ACS ... for use in the US under the brand name Brilinta (AstraZeneca, press release, July 20, 2011). Brilinta is indicated for use in patients during the ...

Jul, 2014 59 pages
Bococizumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 US$ 3,495.00

... has released its new PharmaPoint Drug Evaluation report, “Bococizumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023”. The current ... medically and financially. GlobalData anticipates that Pfizer’s PCSK9 mAb, bococizumab (PF-04950615), will be the third-to-market PCSK9 inhibitor behind Amgen ...

Jul, 2014 85 pages
Angiomax (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 US$ 3,495.00

... Coronary Syndrome) - Forecast and Market Analysis to 2023 SUMMARY GlobalData has released its new PharmaPoint Drug Evaluation report, “Angiomax (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023”. The current ACS market - primarily comprised of antithrombotics, antihypertensives, and statins ...

Jul, 2014 59 pages
Anacetrapib (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 US$ 3,495.00

... has released its new PharmaPoint Drug Evaluation report, “Anacetrapib (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023”. The current ... (Determining the Efficacy and Tolerability of Cholesteryl Ester Transfer Protein [CETP] Inhibition with Anacetrapib) Phase III study demonstrated the ability ...

Jul, 2014 88 pages
Alirocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 US$ 3,495.00

... GlobalData has released its new PharmaPoint Drug Evaluation report, “Alirocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023”. The current ACS ... flush with new mAbs. In its current state, GlobalData expects that alirocumab will be the second-to-market PCSK9, following Amgen’s PCSK9 mAb, ...

Jul, 2014 91 pages
Market Snapshot: Transcatheter Heart Valve 2007 to 2020 - Europe (Germany, France, Italy, UK, Spain) US$ 1,750.00

... , France, Italy, UK, Spain) Summary GBI Research’s report, “Market Snapshot: Transcatheter Heart Valve 2007 to 2020 - Europe (Germany, France, Italy, UK, Spain)” provides ... on market size for the transcatheter heart valves Annualized sales data by revenue for the 2007–2020 period and company share data by ...

Aug, 2014 27 pages
Cardiovascular Risk Factors-Pipeline Insights, 2014 US$ 1,250.00

SUMMARY DelveInsight’s,“ Cardiovascular Risk Factors-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Cardiovascular Risk ...

Aug, 2014
Cardiovascular Inflammation-Pipeline Insights, 2014 US$ 1,250.00

SUMMARY DelveInsight’s,“ Cardiovascular Inflammation-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Cardiovascular Inflammation. This ...

Aug, 2014
Cardiomyopathy-Pipeline Insights, 2014 US$ 1,250.00

SUMMARY DelveInsight’s,“ Cardiomyopathy-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Cardiomyopathy. This report provides information ...

Aug, 2014
South Africa Interventional Cardiology Market Trends and Forecast To 2019 US$ 2,100.00

This research report provides key market trends, market forecasts and competitive scenario of the Interventional Cardiology in South Africa through 2019. The ... Devices (ACDs) Scope The report highlights historic and forecasted market size in terms of revenues & unit sales, average selling price, growth ...

May, 2014 45 pages
South Africa Heart Valve and Repair Market Trends and Forecast To 2019 US$ 2,100.00

... key market trends, market forecasts and competitive scenario of the cardiovascular heart valve and repair in South Africa through 2019. The product categories covered in this report include: Heart Valve Annuloplasty Rings Scope The report highlights historic and forecasted market ...

May, 2014 30 pages
China Interventional Cardiology Market Analysis - Size, Share, Growth, Trends and Forecast Through 2006 - 2019 US$ 2,100.00

This research report provides key market trends, market forecasts and competitive scenario of the Interventional Cardiology in China through 2019. The product ... Devices (ACDs) Scope The report highlights historic and forecasted market size in terms of revenues & unit sales, average selling price, growth ...

May, 2014 45 pages
China Heart Valve and Repair Market Analysis, Size, Share, Growth, Trends and Forecast Through 2006 - 2019 US$ 2,100.00

... key market trends, market forecasts and competitive scenario of the cardiovascular heart valve and repair in China through 2019. The product categories covered in this report include: Heart Valve Annuloplasty Rings Scope The report highlights historic and forecasted market size ...

May, 2014 30 pages
Canada Interventional Cardiology Market Opportunity and Growth Trends Forecast Till 2019 US$ 2,100.00

This research report provides key market trends, market forecasts and competitive scenario of the Interventional Cardiology in Canada through 2019. The product ... Devices (ACDs) Scope The report highlights historic and forecasted market size in terms of revenues & unit sales, average selling price, growth ...

May, 2014 45 pages
Canada Heart Valve and Repair Market Opportunity and Growth Trends Forecast Till 2019 US$ 2,100.00

... key market trends, market forecasts and competitive scenario of the cardiovascular heart valve and repair in Canada through 2019. The product categories covered in this report include: Heart Valve Annuloplasty Rings Scope The report highlights historic and forecasted market size ...

May, 2014 30 pages
Australia Joint Reconstruction Market Analysis - Size, Share, Growth, Trends and Forecast Through 2006 - 2019 US$ 2,100.00

This research report provides key market trends, market forecasts and competitive scenario of the joint reconstruction in Australia through 2019. The product ... comparison for product categories, historic and forecast through 2019. Market share of companies. Average selling price ($) for each product type ( ...

May, 2014 52 pages
Australia Interventional Cardiology Market Forecast and Opportunity Assessment, 2006 - 2019 US$ 2,100.00

This research report provides key market trends, market forecasts and competitive scenario of the Interventional Cardiology in Australia through 2019. The product ... revenues & unit sales, average selling price, growth rates, and company market shares. Highlights and compares key product categories for growth ...

May, 2014 45 pages
Australia Heart Valve and Repair Market Forecast and Opportunity Assessment, 2006 - 2019 US$ 2,100.00

... key market trends, market forecasts and competitive scenario of the cardiovascular heart valve and repair in Australia through 2019. The product categories covered in this report include: Heart Valve Annuloplasty Rings Scope The report highlights historic and forecasted market ...

May, 2014 30 pages
Asia Pacific Cardiovascular Devices Market Forecast To 2019 US$ 4,200.00

... report provides critical market data for cardiovascular devices and its product categories for the Asia Pacific region and its ... ) Biological Heart Valve (Bioprosthetic Heart Valve (BHV) Annuloplasty Rings Cardiovascular Monitoring Systems ECG Monitoring Equipment (Electrocardiogram) ECG Stress Testing ...

May, 2014 166 pages
Antihypertensive Therapeutics in Major Developed Markets to 2020 - Increased Uptake of Combination Therapies to Offset Effects of Key Patent Expiries US$ 4,995.00

... of Key Patent Expiries Summary GBI Research, the leading business intelligence provider, has released its latest research, '‘Antihypertensive Therapeutics in Major Developed Markets to 2020 - Increased Uptake of Combination Therapies to Offset Effects of Key Patent Expiries'’, which provides in-depth ...

Jun, 2014 91 pages
Heart Attack - Pipeline Review, H1 2014 US$ 2,000.00

... Summary Global Markets Direct’s, ‘Heart Attack - Pipeline Review, H1 2014’, provides an overview of the Heart Attack’s therapeutic pipeline. This report provides ... & other developmental activities The report reviews key players involved in the therapeutics development for Heart Attack and enlists all their ...

Apr, 2014 47 pages
France Cardiac Assist Procedures Outlook to 2020 US$ 175.00

... ’s new report, 'France Cardiac Assist Procedures Outlook to 2020', provides key procedures data on the France Cardiac Assist Procedures. The report ... models. GlobalData uses epidemiology based models to estimate and forecast the procedure volumes. The objective is to provide information that represents the most ...

May, 2014 22 pages
Cardiovascular Deals and Alliances of 2013 US$ 1,495.00

The Cardiovascular Deals and Alliances of 2013 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered ... signed by bigpharma and bigbiotech, and most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online ...

Aug, 2014 200 pages
Sectoral Capsule-The Heart of the Matter-Cardiovascular Market in India US$ 250.00

The capsule reports are concise information about the industry; and the opportunities & challenges that it carries. It gives the past as well as ... of the industry with all relevant inputs in place. The dynamics that propel the sector, namely, opportunities, competition, infrastructure investment and regulatory ...

Jan, 2014 16 pages
Ventricular Tachycardia Global Clinical Trials Review, H2, 2013 US$ 2,500.00

... and data relating to the clinical trials on Ventricular Tachycardia. It includes an overview of the trial numbers and their recruitment status as per the ... many more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals ...

Dec, 2013 74 pages
Ventricular Fibrillation Global Clinical Trials Review, H2, 2013 US$ 2,500.00

... and data relating to the clinical trials on Ventricular Fibrillation. It includes an overview of the trial numbers and their recruitment status as per the ... many more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals ...

Dec, 2013 60 pages
Venous Thromboembolism Global Clinical Trials Review, H2, 2013 US$ 2,500.00

... and data relating to the clinical trials on Venous Thromboembolism. It includes an overview of the trial numbers and their recruitment status as per the ... many more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals ...

Dec, 2013 125 pages
Thromboembolism Global Clinical Trials Review, H2, 2013 US$ 2,500.00

... Summary GlobalData's clinical trial report, 'Thromboembolism Global Clinical Trials Review, H2, 2013' provides data on the Thromboembolism clinical trial scenario. This ... and many more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / ...

Dec, 2013 175 pages
Regurgitation Global Clinical Trials Review, H2, 2013 US$ 2,500.00

... 2013 Summary GlobalData's clinical trial report, 'Regurgitation Global Clinical Trials Review, H2, 2013' provides data on the Regurgitation clinical trial scenario. This ... and many more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities ...

Dec, 2013 87 pages
1 2 3 4 5 >
Skip to top